Loading…
Employees: 900
Size Katakura Industries (3001.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $791M, the 846th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,755 on 6 Nov 2026.
Performance Over six months the shares gained 46.1%, against -9.5% for the median peer and +1.8% for the Japan market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 0.5% over the last twelve months (peer median +2.7%); the operating margin is 15.8% (peer median 7.3%).
Valuation It trades at 2.5× enterprise value to sales against a peer median of 2.8× (10th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥40.7B | ¥40.7B | ¥39.4B | ¥40.0B | ¥34.3B |
| Revenue growth | — | +3% | -1% | +17% | — |
| Gross profit | ¥15.1B | ¥14.4B | ¥14.5B | ¥15.1B | ¥12.6B |
| EBITDA | ¥9.39B | ¥8.76B | ¥6.95B | ¥6.46B | ¥4.05B |
| Net income | ¥7.59B | ¥5.76B | ¥3.52B | ¥3.04B | ¥2.82B |
| Free cash flow | n/a | ¥5.66B | ¥3.65B | ¥2.50B | -¥1.70B |
| Capital expenditure | n/a | ¥2.67B | ¥2.06B | ¥1.11B | ¥1.05B |
| Total debt | ¥6.63B | ¥8.95B | ¥11.0B | ¥12.6B | ¥14.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3001.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.2% | -3.6% | highest of 20 |
| 6-month return | +46.1% | -9.5% | highest of 20 |
| Distance from 52-week high | -9.1% | -32.1% | 2nd highest of 20 |
| Revenue growth (TTM) | +0.5% | +2.7% | 9th lowest of 19 |
| Operating margin | 15.8% | 7.3% | 5th highest of 19 |
| EV / Sales | 2.5× | 2.8× | 10th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 0.2% | -1.1% | 6th most demanding of 12 |
| Growth delivered (Del g) | +0.5% | +2.6% | 5th lowest of 12 |
| Hurdle (Req g minus delivered) | -0.3 pp | -2.2 pp | 5th most demanding of 12 |
| ROIC minus cost of capital | +0.8 pp | +0.3 pp | 9th highest of 17 |
| EV / EBITDA | 10.6× | 11.4× | 4th cheapest of 9 |
| Net debt / EBITDA | -2.9× | -0.4× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | 0.4× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | 32.3× | n/a | n/a |